Treatment of the hemolytic uremic syndrome with plasma.
Two patients with the hemolytic uremic syndrome were treated with plasma exchange an infusion: in both cases, the reduced platelet count reverted to normal values and the microangiopathic anemia ceased within a few days. Systemic blood pressure and requirement for antihypertensive drug therapy were also markedly reduced following treatment with plasma. Venousprostacyclin (antiplatelet aggregating) activity was undetectable in both patients before but was restored after treatment with plasma. The plasma samples collected before, but not those collected at various intervals after replacement therapy, had decreased capacity to stimulate prostacyclin activity in rat aortic rings. It is suggested that in patients with the hemolytic uremic syndrome or with other clinical conditions which can be included under this rubric (such as thrombotic thrombocytopenic purpura) a plasma factor is lacking which stimulates prostacyclin activity. Plasma would supply such a missing factor, thus representing a rational treatment for some of the life-threatening manifestations (thrombocytopenia, hemolytic anemia, hypertension) of this severe syndrome.
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D011464:Epoprostenol / Q000097:blood*; D005078:Exchange Transfusion, Whole Blood; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010949:Plasma; D011453:Prostaglandins / Q000097:blood*
D000959:Antihypertensive Agents; D011453:Prostaglandins; D011464:Epoprostenol